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Abstract
Background: The relative scale adjusts for baseline variability and therefore may lead to findings that can be
generalized more widely. It is routinely used for the analysis of binary outcomes but only rarely for continuous
outcomes. Our objective was to compare relative vs absolute scale pooled outcomes using data from a recently
published Cochrane systematic review that reported only absolute effects of inhaled β2-agonists on exercise-
induced decline in forced-expiratory volumes in 1 s (FEV1).
Methods: From the Cochrane review, we selected placebo-controlled cross-over studies that reported individual
participant data (IPD). Reversal in FEV1 decline after exercise was modeled as a mean uniform percentage point (pp)
change (absolute effect) or average percent change (relative effect) using either intercept-only or slope-only,
respectively, linear mixed-effect models. We also calculated the pooled relative effect estimates using standard
random-effects, inverse-variance-weighting meta-analysis using study-level mean effects.
Results: Fourteen studies with 187 participants were identified for the IPD analysis. On the absolute scale, β2-
agonists decreased the exercise-induced FEV1 decline by 28 pp., and on the relative scale, they decreased the FEV1
decline by 90%. The fit of the statistical model was significantly better with the relative 90% estimate compared
with the absolute 28 pp. estimate. Furthermore, the median residuals (5.8 vs. 10.8 pp) were substantially smaller in
the relative effect model than in the absolute effect model. Using standard study-level meta-analysis of the same 14
studies, β2-agonists reduced exercise-induced FEV1 decline on the relative scale by a similar amount: 83% or 90%,
depending on the method of calculating the relative effect.
Conclusions: Compared with the absolute scale, the relative scale captures more effectively the variation in the
effects of β2-agonists on exercise-induced FEV1-declines. The absolute scale has been used in the analysis of FEV1
changes and may have led to sub-optimal statistical analysis in some cases. The choice between the absolute and
relative scale should be determined based on biological reasoning and empirical testing to identify the scale that
leads to lower heterogeneity.
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Background
The relative scale has been used for decades for estimat-
ing the effects on binary outcomes, such as calculating
that heavy alcohol consumption increases the occur-
rence of liver cirrhosis by the rate ratio (RR) of over 10
[1]. It is also standard for survival analysis, using hazard
ratios, and for comparisons of incidence rates, using in-
cidence rate ratios. Meta-analyses have shown that the
relative scale leads to less heterogeneity in the analysis
of binary outcomes compared with the absolute scale
(i.e. rate differences), which indicates that the relative
scale better captures the biological effects [2]. In con-
trast, the relative scale has rarely been used in the meta-
analysis of continuous outcomes and it is not available
as an option in popular meta-analysis software such as
the RevMan program of the Cochrane collaboration [3].
Instead, meta-analyses of continuous outcomes typically
use the absolute scale, i.e., the original measurement
units (mean difference, MD), or the standardized mean
difference (SMD) scale in which the mean difference is
expressed in the pooled standard deviation units. Both
of these approaches (MD and SMD) are available as
options in popular meta-analysis software [3].
The selection of scale for continuous outcomes is rele-
vant in the analysis of a single trial and in the meta-
analysis of several trials. In a single trial, the scale influ-
ences the interpretation of the findings and the communi-
cation between researchers, clinicians and patients [4]. In
the case of a meta-analysis, the scale additionally influ-
ences the comparability of the trials, namely, the relative
scale adjusts for the baseline variability in continuous out-
comes in the same sense as the pooled RR adjusts for the
baseline variability in risk between different studies in the
analysis of binary outcomes. In meta-analyses that pooled
diverse research topics of continuous outcomes, hetero-
geneity was less on the relative scale, than on the absolute
scale [5–7]. This suggests that the relative scale may better
capture also many biological effects that are measured
using continuous outcomes. As one illustration, the rela-
tive scale was demonstrated to be more informative in the
analysis of disease duration compared with using the MD
scale [8–10].
The current study was motivated by the Cochrane re-
view by Bonini et al., which examined the effects of β2-
agonists on exercise-induced bronchoconstriction (EIB)
[11]. The usual limit for classifying that a person has the
condition EIB is a ≥ 10% decline in forced expiratory
volume in 1 s (FEV1) in a standardized exercise test [12].
Based on 72 comparisons from 44 studies, Bonini et al.
calculated that β2-agonists reduced the exercise-induced
FEV1 decline by 17.67 percentage points (pp) (95% CI:
15.84 to 19.51 pp) [11]. However, one person may suffer
from an 11% decline in FEV1 by exercise and another
person may suffer from an 80% decline in FEV1, yet both
of them are similarly classified as cases of EIB. The
Cochrane review implies that the expected effect of
17.67 pp. reduction in exercise-induced FEV1 decline
applies for both persons. However, it seems likely that
the former person has an effect of β2-agonist much less,
whereas the latter person might have an effect much
greater than the overall mean of 17.67 pp. reduction in
FEV1 decline.
The β2-agonists were invented in the middle of the
1900s and their efficacy against EIB was demonstrated in
numerous clinical trials starting from the 1970s [12–16].
Thus, it is not relevant to ask the null hypothesis type of
question whether β2-agonists differ from placebo in their
influences on EIB. Instead, the important question is to
estimate the average size of the effect and the variation
in effect size between individuals.
The goal of this study was to compare the usefulness
of the relative and the absolute scales in the estimation
of the effects of β2-agonists on exercise-induced FEV1
decline. If the relative scale better captures the effects of
interventions on FEV1 changes, then the meta-analyses
that have used an absolute scale such as MD for analyz-
ing the effects on FEV1 changes [11] may have led to
sub-optimal estimates.
Methods
Selection of the β2-agonist trials on EIB
No new literature search was done for this analysis, since
Bonini et al. [11] carried out recently a thorough search of
the literature on controlled trials of β2-agonists for EIB.
For the independent participant data (IPD) analysis,
we systematically reviewed all the included and excluded
studies, and their reference lists in the studies identified
by Bonini et al. [11], and included all placebo-controlled
inhalatory β2-agonist cross-over randomized trials that
reported IPD, 13 trials [17–29]. Bonini et al. excluded
trials for a few reasons, one being “no clear diagnosis of
exercise-induced bronchoconstriction”. We did not ex-
clude such trials for the following reasons: clear dichot-
omous definition of EIB, such as a ≥ 10% or a ≥ 15%
FEV1 decline in an exercise test [12] is relevant in cer-
tain contexts such as in top level athletics; however, such
a cut-off level is arbitrary and has no biological basis,
and dichotomization of continuous variables decreases
statistical power. Moreover, if participants with small
FEV1 declines are included in the analysis, the range of
FEV1 declines becomes wider and the comparison of the
absolute scale (intercept) and the relative scale (slope)
becomes statistically more powerful. One trial that was
excluded by Bonini et al. on the basis that there was no
clear diagnosis of EIB reported IPD for exercise-induced
FEV1 decline and was included in our IPD analysis [22].
Another trial with IPD data was identified through per-
usal of the reference lists in included RCTs, and was
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included in our analysis [30], but had not been identified
by Bonini [11]. Thus, a total of 14 trials reporting IPD
suitable for this analysis were identified (Table 1).
For the study-level linear mixed-effect models, we
included all the 44 cross-over trials that were included in
the Analysis 1.1 of Bonini [11]. The characteristics of the
44 trials were described previously [11], and are not sum-
marized in this report. For the standard study-level meta-
analyses, we included the 14 trials that reported IPD.
Extraction of data
When several β2-agonists were investigated in the same
report, we selected salbutamol if that was used; and if not,
salmeterol, in an attempt to decrease the heterogeneity of
the comparisons. When exercise tests were repeated
several times after the administration of a β2-agonist, we
selected the shortest delay between the β2-agonist admin-
istration and the exercise test. In some trials, β2-agonists
were administered for several days or weeks, and we
selected the shortest administration before the exercise
test. There have been discussions about whether the most
appropriate baseline in an EIB study is before drug admin-
istration (pre-drug) or after drug administration (post-
drug) [31, 32]. In cases when both levels were available,
we selected the pre-drug level as the baseline.
For the IPD analysis, individual exercise-induced FEV1
declines were extracted from the 14 trial reports. Two
studies reported IPD results as figures and the FEV1
declines were measured from them [25, 26]. For the
study-level mixed-effect model analysis of the 44 trials,
we extracted the numerical values for FEV1 declines
from the reports, or measured the mean FEV1 declines
from published figures when numerical data were not
published. See Additional file 1: Table S1 and Table S2 for
description of the details in the selections of the IPD and
study means, and see Additional file 2 for the extracted
data. Some inaccuracies and errors in data extraction in
Bonini et al. [11] were identified and corrected if required,
see Additional file 1: Table S4.
Statistical methods
The absolute effect of a β2-agonist for a single partici-
pant was measured as the percentage point (pp) differ-
ence in the maximal exercise-induced FEV1 percent
decline after β2-agonist treatment minus the maximal
exercise-induced FEV1 percent decline after placebo
treatment, see Fig. 1 as an illustration.
At the individual level, the relative effect was measured
as the percent of the exercise-induced FEV1 percent de-
cline prevented by β2-agonist treatment. It is calculated
as the absolute effect divided by the maximal exercise-
induced FEV1 percent decline after placebo (Fig. 1).
The usefulness of the absolute scale (intercept) and
the relative scale (slope) in explaining the variation in
β2-agonist effects on FEV1 decline after exercise was an-
alyzed with linear mixed-effects models. The type of β2-
agonist and the identity of the trial were used as cluster-
ing variables for the participants. The lmer function of
the lme4 package of the statistical software R was used
for the mixed-effects modeling [33, 34].
First, the intercept, corresponding to the mean effect of a
β2-agonist on the absolute scale, was included in the statis-
tical model of the IPD, see formula (1) below. Thereafter,
the slope was added, which explains the variation in the β2-
agonist absolute effects on FEV1 decline by the variation in
FEV1 declines after placebo administration (i.e. untreated
FEV1 decline), formula (2) below. Finally, the intercept was
removed, so that the slope remaining alone describes the
mean effect of β2-agonists on the relative scale, formula (3)
below. The models were compared with the anova test and
Akaike Information Criterion (AIC). For the printouts of
the calculations, see Additional file 1.
Definitions (see Fig. 1):
X = FEV1 decline in the placebo test,
Y = absolute difference in FEV1 declines in the β2-
agonist and placebo tests
Yi ¼ αþ εi ð1Þ
Yi ¼ αþ β  Xi þ εi ð2Þ
Yi ¼ β  Xi þ εi ð3Þ
The median and interquartile levels for the relative ef-
fects of β2-agonists were calculated with the rq function
of the quantreg package in R without adding an
intercept [33, 35].
Table 1 Characteristics of included trials with IPD
Trial (year)[ref.] N β2-Agonist
Anderson (2001) [17] 27 Salbutamol
Boner (1994) [18] 15 Salbutamol
de Benedictis (1998) [19] 12 Salbutamol
Henriksen (1992) [20] 12 Salbutamol
Pearlman (2007) [21] 15 Salbutamol
Robertson (1994) [22] 8 Salbutamol
de Benedictis (1996) [23] 12 Salmeterol
Green (1992) [24] 13 Salmeterol
Simons (1997) [25] 11 Salmeterol
Dinh Xuan (1989) [26] 10 Terbutaline
Henriksen (1983) [27] 14 Terbutaline
Debelic (1988) [28] 16 Reproterol
Walker (1986) [29] 12 Bitolterol
Schoeffel (1981) [30] 10 Metaproterenol
All IPD trials 187
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The study-level mixed-effects models were carried out
with the lmer function with the type of β2-agonist being
the clustering variable for studies and by using the num-
ber of participants as the weight for the study means.
Similarly, as in the analysis of the IPD data, first the
intercept was included, then the slope was added, and fi-
nally the intercept was removed.
Standard meta-analysis comparing the relative and ab-
solute scales was performed using the generic inverse
variance and random effects options of the RevMan pro-
gram [3]. The meta-analyses were restricted to the 14
trials with the IPD, since the absolute mean effect on the
FEV1 decline and the standard error (SE) for the differ-
ence could be calculated accurately from the individual
paired differences from the IPD.
For the standard meta-analysis, the relative effects of in-
dividual trials were calculated in two ways, see Additional
file 1: Table S3. First, the absolute mean effect and its SE
(see above) were divided by the exercise-induced FEV1 de-
cline after the placebo. If there was no absolute mean ef-
fect, this leads to a 0% relative effect; and if all FEV1
decline was fully prevented, this leads to a 100% effect.
Second, the relative effect and its SE were derived from
the slopes of the linear regression models of the 14 trials,
see Additional file 1. We used the χ2 test and the I2 statis-
tic to assess statistical heterogeneity among the trials in
each meta-analysis [36]. A value of I2 greater than about
70% indicates a high level of heterogeneity.
To estimate the potential role of the regression to the
mean phenomenon as a cause for the slope between the
effect of β2-agonists and the placebo-test FEV1 decline
in Fig. 2, we used three approaches. The slope generated
by regression to the mean depends on the within-subject
SD of the placebo-test FEV1 decline and the β2-agonist-
test FEV1 decline, and on the between-subject SD of the
placebo-test FEV1 decline [37]. Thus, regression to mean
is independent of the size of treatment effect. Therefore,
we first estimated the slope generated by regression to
the mean by comparing two different placebo-test FEV1
declines of 45 participants of four studies [20, 23, 24,
30]. Second, we used the Blomqvist formula to calculate
the corrected slope [37]. Third, we calculated from for-
mula (1) in Hayes paper [37] the magnitude of within-
subject SD that would be needed to generate the ob-
served slope by the regression to mean phenomenon.
Two-tailed P-values were used.
Results
Analyses of the IPD
Fourteen placebo-controlled cross-over comparisons
were identified that reported the IPD of the effects of
β2-agonists on exercise-induced FEV1 decline (Table 1).
In all they included 187 participants. Six trials with 89
participants used salbutamol (albuterol) [17–22], 3 trials
with 36 participants used salmeterol [23–25], 2 trials
with 24 participants terbutaline [26, 27], 1 trial with 16
participants reproterol [28], 1 trial with 12 participants
bitolterol [29] and 1 trial with 10 participants used meta-
proterenol (orciprenaline) [30].
The included trials administered placebo and β2-agon-
ist to the same participants in a cross-over design. The
exercise challenge was carried out thereafter and the
Fig. 1 Description of the pulmonary function measurements on which the IPD analysis is based. The exercise-induced decline in FEV1 was
measured on two occasions: after the administration of placebo and after the β2-agonist. The figures are for the participant X shown in Fig. 2.
The FEV1 declines after placebo and after β2-agonist lead to an absolute effect of 41 percentage point (pp) less decline in FEV1 (based on 70–29),
and to a relative effect of 58% less decline after the β2-agonist (based on 41/70). If there was no absolute mean effect, this leads to a 0% relative
effect (0/70 = 0), and if all FEV1 decline was fully prevented, this leads to a 100% effect (70/70 = 1)
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post-exercise decline in FEV1 was measured. Figure 1
demonstrates the calculation of the absolute effect of β2-
agonist for participant X, who is also indicated in Fig. 2.
The level of exercise-induced FEV1 decline in the pla-
cebo test is shown on the horizontal axis of Fig. 2 for
each individual participant in the 14 IPD studies. After
placebo, the FEV1 changes caused by exercise ranged
from an 82% decrease to a 2% increase, with the median
of a 31% decrease. The absolute effect of the β2-agonist
for each individual was calculated as the percentage
point (pp) difference in the FEV1 decline after the β2-
agonist and after the placebo. For example, participant X
on the left-hand side of Fig. 2 had an exercise-induced
FEV1 decline of 70% after placebo, and a decline of 29%
after salbutamol, which indicates a 41 percentage point
(pp) improvement (based on 70–29), as the effect of
salbutamol on the absolute scale, see also Fig. 1. On the
relative scale, the FEV1 decline of the same person was
reduced by 58%, based on the ratio of 41/70.
On the relative scale, the 0% effect indicates that the
β2-agonist has no effect, i.e., the FEV1 decline after β2-
agonist is identical to the FEV1 decline after placebo.
The 100% effect indicates full protection so that exercise
after β2-agonist causes no decline in FEV1, i.e., the FEV1
decline occurring after placebo is fully reversed by the
β2-agonist. These two limits are shown in Fig. 2 by the
dashed lines. Ten participants showed β2-agonist effects
below 0% which means that exercise-induced FEV1 de-
cline in the β2-agonist test was greater than in the placebo
test. Probably this is explained by random variation. Sixty-
four participants showed β2-agonist effects over 100%
which means that FEV1 level after exercise in the β2-agon-
ist test was greater than the FEV1 level before exercise. In
addition to random variation, this finding is also explained
Fig. 2 The effect of β2-agonists on exercise-induced bronchoconstriction in the IPD analysis. Each dot indicates one participant. The exercise-
induced FEV1 decline after placebo is shown on the horizontal axis. The absolute effect of a β2-agonist is defined as the percentage point (pp)
difference in the FEV1 declines after placebo and after β2-agonist, and is shown on the vertical axis, compare with Fig. 1. Lack of any effect of β2-
agonist is indicated by the horizontal dashed line at the level of 0 pp., corresponding also to the relative effect of 0% (i.e. the FEV1 decline after
β2-agonist is identical to the FEV1 decline after placebo treatment). Full removal of exercise-induced FEV1 decline is indicated by the upper
diagonal dashed line corresponding to the relative effect of 100% (i.e. the FEV1 decline after placebo treatment is fully reversed after β2-agonist
treatment). The mean absolute effect, defined by the intercept alone, is shown by the horizontal solid line at the level of 28 pp. The mean relative
effect, defined by the slope alone, is shown by the diagonal solid line at the level of 90%. Abbreviations: pp., percentage points
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by our usage of the pre-drug level as the baseline. For
many participants β2-agonist increased pre-exercise FEV1
level and if exercise-induced FEV1 decline is simultan-
eously prevented, this would lead to effects above 100% in
the calculation of the relative effects.
The distribution of the data points in Fig. 2 suggests that
the absolute effect of β2-agonist on FEV1 decline appears
to be greater in study participants with larger baseline
exercise-induced FEV1 declines after placebo on the left-
hand side of the graph. This is tested explicitly below by
initially fitting the data using only a single intercept which
is equivalent to describing the effect of β2-agonist on
exercise-induced FEV1 decline as a single average percent-
age point improvement akin to an absolute scale approach
used by Bonini et al. [11]. Thereafter we fit the data using
a slope to derive an average proportion of exercise-
induced FEV1 decline that is reversed by β2-agonist treat-
ment which accounts for differing baseline exercise-
induced FEV1 declines akin to a relative scale approach.
The usefulness of the absolute scale (intercept) and the
relative scale (slope) were compared with linear mixed-
effects models shown in Table 2. When only the intercept
was included, the β2-agonists reduced the FEV1 decline by
an average of 28 pp. This intercept indicates the mean ef-
fect on the absolute scale. When the slope was added, the
fit of the model was improved substantially. Furthermore,
addition of the slope caused the estimate of the intercept
to decrease substantially. When the intercept was re-
moved from the model, the change in the fit of the model
was much smaller compared with the addition of the
slope. In addition, the lower AIC value also indicates that
the model with the slope alone is better than the model
with the intercept alone (Table 2). The slope of − 0.90 in-
dicates that β2-agonist treatment reduced the exercise-
induced FEV1 decline by 90% on the relative scale. The
absolute effect (intercept alone) and the relative effect
(slope alone) obtained from the mixed-effects models are
shown in Fig. 2 as continuous solid lines.
A further measure to compare the relative scale (slope)
and the absolute scale (intercept) was the magnitude of the
residuals of the models. For the absolute effect of the uni-
form 28 pp. decrease in FEV1 decline, the median residual
was 10.8 pp. For the relative effect of the 90% decrease in
FEV1 decline, the median residual was just 5.8 pp. This also
illustrates that the relative effect (slope) captures much bet-
ter the individual-level variation in the effects of β2-ago-
nists than the absolute effect (intercept).
Variation in the effects of the β2-agonists was also ana-
lyzed by stratifying participants to categories by the post-
exercise FEV1 declines after placebo administration. Over
the 5 categories shown in Table 3, there is a 3-fold vari-
ation in the absolute mean effect of the β2-agonists be-
tween the extremes ranging from 15.2 pp. in the category
with the lowest FEV1 decline after placebo administration
to 44.3 pp. in the category with the highest FEV1 decline
after placebo administration. The confidence intervals of
the first, fourth and fifth groups are inconsistent with the
overall mean absolute effect of 28 pp. decrease in FEV1
decline (Fig. 2). However, the confidence intervals of the
relative effects of all the 5 categories are overlapping and
consistent with the confidence interval of the overall 90%
mean effect calculated from the slope of the linear regres-
sion model (Fig. 2, Table 2).
The distribution of the individual-level relative effect
of β2-agonists was skewed with skewness of − 1.05
(Fig. 3). Therefore, the median effect might be a more
informative descriptive measure of typical effect than the
mean. The median relative effect over the 187 partici-
pants was an 88% reduction in FEV1 decline, with the
interquartile range from 60% to 103%. Although the me-
dian is close to the mean estimate (90%), the asymmetry
is apparent in the interquartile range.
Estimation of the possible role of the regression to
the mean
Regression to the mean is a potential confounder in the
analysis of change by baseline values [37]. We used three
approaches to evaluate the possible bias in the slope in
Fig. 2 caused by regression to the mean.
First, four studies with a total of 45 participants car-
ried out two separate placebo-exercise tests and they can
be used to estimate the size of slope caused by regres-
sion to the mean when there is no treatment effect, and
a slope of − 0.153 was observed, which is substantially
smaller than the slope of − 0.691 for the model with
slope and intercept (Table 2).
Second, the within-subject SD for the placebo-test
FEV1 decline from the four studies was 6.23 pp. and the
Table 2 Comparison of the intercept and slope to explain the effect of β2-agonists by IPD
Intercept Slope χ2(3 df) * P * AIC **
Uniform effect (absolute scale) 27.7 – 1638.3
Intercept and slope 7.9 −0.69 82.3 10−17
Slope (relative scale) – −0.90 13.9 0.003 1576.8
The intercept and the slope were calculated with a linear mixed-effects model using the type of β2-agonist and study as grouping variables. The intercept alone
indicates that β2-agonists decrease the post-exercise FEV1 decline by an absolute effect of 27.7 pp. (95% CI: 22.1 to 33.4 pp). The slope alone indicates that β2-
agonists decrease the post-exercise FEV1 decline by a relative effect of 90% (95% CI: 72% to 109%). Abbreviations: pp., percentage points
* Anova test comparing the model on the row with the model on the row above
** AIC, Akaike information criterion. AIC estimates the relative quality of statistical models, lower AIC value is preferable
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observed between-subject SD for all 187 participants was
18.9 pp. The Blomqvist formula can be used to estimate
the true slope from the previous SD values [37], and the
estimated true slope in Fig. 2 is − 0.653, which is minim-
ally different from our calculated slope of − 0.691 (95% CI:
− 0.477 to − 0.910) for the model with slope and intercept
(Table 2). In contrast, applying the Blomqvist formula to
the slope of − 0.153 of the placebo-placebo comparison of
the previous paragraph, the true slope becomes − 0.049
which is very close to the null slope as expected.
Third, we calculated that to generate a slope of − 0.69,
the within-subject SD for the measurement of FEV1 de-
cline should be up to 28 pp., which is over 4 times the
observed within-subject SD (ie 6.23 pp).
Thus, on the basis of these three approaches, the size
of the regression to the mean phenomenon is so small
that it has no practical relevance in our analysis of the
IPD in Fig. 2.
Analysis of study-level data by the mixed-effects models
The study-level mixed-effects model was focused on the
44 cross-over trials [11] which reported the mean
exercise-induced FEV1 decline after β2-agonist and after
placebo (Fig. 4). The study mean FEV1 declines after the
placebo ranged from − 46% to − 9% with a median
decline of − 27%. The range of the data points is much
narrower compared with the range of the IPD (Fig. 2),
resulting in the study-level analysis having less statistical
power to compare the absolute and relative scales. Un-
like the data points in Fig. 2, given the narrower range
of FEV1 declines after placebo along the x-axis in Fig. 4,
it is less clear whether the effect of β2-agonist on FEV1
decline is greater in studies with larger mean baseline
exercise-induced FEV1 declines after placebo.
Testing this formally, the intercept of the study-level
analysis indicated a mean uniform 21 pp. reduction in
exercise-induced FEV1 decline by β2-agonists (Fig. 4).
The slope indicates a 77% reduction in exercise-induced
FEV1 decline by β2-agonists. Analysis of the study-level
data suggests that the intercept might be more consist-
ent with the data (Table 4).
Standard meta-analysis of study-level data
Standard meta-analyses comparing the absolute and two
relative scales were limited to the 14 trials which re-
ported IPD as these allowed calculation of individual
paired differences and their SE values. The calculation of
the 95% CIs by the absolute scale and the two relative
scales is illustrated in Additional file 1: Table S3.
Table 3 Analysis of β2-agonist effects on FEV1 decline in categories of placebo-test FEV1 declines
FEV1 decline after placebo (range) Mean FEV1 decline after placebo Absolute effect on FEV1 decline (pp) (95% CI) Relative effect (95% CI) N
10–19% 15.5% 15.2 (10.2–20.3) 0.99 (0.79–1.24) 33
20–29% 24.7% 23.6 (17.7–29.9) 0.92 (0.74–1.14) 29
30–39% 34.5% 33.0 (25.0–40.9) 0.95 (0.78–1.15) 34
40–49% 44.5% 39.7 (30.6–49.3) 0.83 (0.69–1.00) 29
50–83% 59.9% 44.3 (34.8–54.6) 0.71 (0.60–0.84) 34
Footnote: this table is restricted to 159 participants who had exercise-induced FEV1 decline of ≥10% in the placebo test. The 95% CI for the relative effect was
calculated with the approach described in [5], see Additional file 1. Abbreviations: pp., percentage points
Fig. 3 Distribution of the individual-level relative effects of β2-agonists on exercise-induced FEV1 declines. This figure is limited to 159 participants
who had ≥10% decline in FEV1 by exercise in the placebo test. Participants with small FEV1 declines are not informative in the calculation of
participant-level relative effect. In addition, the 10% limit is usual for the diagnosis of exercise-induced bronchoconstriction [12]. Participant X of
Figs. 1 and 2 has value 0.58 (58%) in this figure. As in Fig. 2, some participants showed β2-agonist effects below 0% or over 100%
Hemilä and Friedrich Systematic Reviews           (2019) 8:282 Page 7 of 13
There is substantial heterogeneity between the trials
on the absolute scale with I2 = 81% (Fig. 5a). The esti-
mate of a uniform 25 pp. mean reduction is similar to
the absolute scale estimate from the mixed-effects model
using IPD (Table 2).
The study-level relative effects were first obtained by div-
iding the absolute effect by the exercise-induced FEV1
decline in the placebo test for each study prior to pooling,
see Additional file 1: Table S3 for the explanation of this
transformation. In this approach the heterogeneity between
the studies was also I2 = 81% (Fig. 5b). This approach
indicates that β2-agonists reduced exercise-induced FEV1
decline by 83%. This estimate is similar to the mean effect
on the relative scale in the mixed-effects model using IPD
(Table 2). There is no substantial difference in the statis-
tical significance between the relative effect calculated in
this way (Z = 9.7: Fig. 5b) compared with the pooled abso-
lute effect (Z = 9.5; Fig. 5a).
The relative effects of the IPD studies were also ob-
tained from the slopes of linear regression models similar
Fig. 4 The effect of β2-agonists on exercise-induced bronchoconstriction in the study-level analysis. The studies in this analysis are the same as
those in the Analysis 1.1 of Bonini et al. [11]. Each circle indicates one study and the area of the circle is proportional to the number of
participants and represents the weighting of the study in calculating the mean absolute and relative effects. See Fig. 2 for the description of the
lines in this figure. The mean absolute effect, defined by the intercept alone, is shown by the horizontal solid line at the level of 21 pp. The mean
relative effect, defined by the slope alone, is shown by the diagonal solid line at the level of 77%. For the identity of the 44 trials and their
references, see Additional file 1: Table S2 and [11]. Abbreviations: pp., percentage points
Table 4 Comparison of the intercept and slope to explain the effect of β2-agonists by study means
Intercept Slope χ2(3 df) * P * AIC **
Uniform effect (absolute scale) 21.4 – 323.5
Intercept and slope 16.4 −0.24 8.52 0.036
Slope (relative scale) – −0.77 11.9 0.010 333.0
The intercept and the slope were calculated with a linear mixed-effects model using the type of β2-agonist as the grouping variable. The studies were weighted
by the square root of the number of participants. For the identity of the 44 trials and their references, see Additional file 1: Table S2 and [11]. Abbreviations: pp.,
percentage points
* Anova test comparing the model to the model in the row above
** AIC, Akaike information criterion. AIC estimates the relative quality of statistical models, lower AIC value is preferable
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to the analysis presented in Fig. 2, however, now for each
of the individual trials separately (Fig. 5c). For most stud-
ies, this approach led to smaller SE values compared to
the Fig. 5b analysis. The smaller SE values increased the
heterogeneity between the studies to I2 = 92%, yet concur-
rently increased the precision of the pooled estimate sub-
stantially (Z = 16.0; Fig. 5c), compared with Fig. 5a and b.
This approach indicates that β2-agonists reduced
FEV1 decline by 90%, identical to the slope estimate
calculated in Table 2.
Discussion
The goal of this study was to compare whether the abso-
lute or the relative scale yields more consistent estimates
Fig. 5 Meta-analysis of the effect of β2-agonists on exercise-induced FEV1 declines a) on the absolute scale, b) on the relative scale based on the
absolute scale, and c) on the relative scale based on the slopes of linear regression models. See Additional file 1: Table S3 for the description of
the calculation of the 95% CIs. In the forest plot on the right-hand side, the vertical line indicates the placebo test level. The horizontal lines
indicate the 95% CI for the β2-agonist effect in the particular trials and the square in the middle of the horizontal lines indicate the point
estimate of the effect in the trial. The sizes of the squares indicate the relative weights of the trials in the pooling of the results. The diamond
shape indicates the pooled effect and its 95% CI. The generic inverse variance and random effects options of the RevMan program were used [3].
See Additional file 1 for the details of the calculations
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of effect, using the example of β2-agonist treatment to
prevent FEV1 declines associated with EIB, the severity
of which can range widely between patients. The abso-
lute scale is routinely used in the analysis of continuous
data and therefore the comparison of these two scales is
relevant more widely than just for the analysis of FEV1
changes.
In people with EIB, Bonini et al. calculated that the β2-
agonists decreased exercise-induced FEV1 decline by
17.67 pp. (95% CI: 15.84 to 19.51 pp) [11]. If EIB was a
homogeneous medical condition, such a uniform effect
might be meaningful. Instead, EIB is highly heteroge-
neous, since it is usually defined by post-exercise FEV1
decline of 10% or more, though other arbitrary cut-off
limits have been used. Thus, in this dichotomization two
persons with 11% and 80% FEV1 declines after exercise
are both classified as having EIB, whereas a person with
a 9% FEV1 decline is not. However, the person who has
the 11% decline probably is biologically much closer to
the person who has the 9% decline compared with the
person who has the 80% FEV1 decline after exercise. It
does not seem reasonable to assume that Bonini’s esti-
mate of 17.67 pp. effect would apply for people with a
low and a high level of exercise-induced FEV1 decline.
Furthermore, dichotomization of continuous variables
decreases statistical power [38–41].
One approach to achieve more personalized effects of
β2-agonists is to categorize people into groups by their
untreated exercise-induced FEV1 decline levels (Table
3). In people who had untreated exercise-induced FEV1
declines in the range from 10% to 19%, β2-agonists re-
duced the FEV1 decline by 15 pp. (95% CI: 10 to 20 pp),
whereas in people who had untreated FEV1 declines in
the range from 30% to 39%, the reduction of the decline
was 33 pp. (95% CI: 25 to 41 pp), and in people who had
untreated FEV1 declines of 40% and greater the percent-
age point improvement was even greater (Table 3). The
confidence intervals of the three groups with FEV1
decrease 30% and greater are all inconsistent with the
17.67 pp. effect calculated by Bonini [11]. These three
groups contain 61% (97 of 159) of the participants in
Table 3. This illustrates that Bonini’s estimate of effect
does not apply to a great proportion of people classified
as having EIB.
The relative scale is most informative in the analysis of
the β2-agonist effects on exercise-induced FEV1 declines
since on the relative scale a single estimate of effect,
expressed as a percentage improvement of the baseline
exercise-induced FEV1 decline (rather than a uniform
percentage point improvement), applies over all study
participants independent of their initial FEV1 decline
levels (Fig. 2, Tables 2 and 3). In our analysis, half of the
participants with IPD had observed β2-agonist effect 5.8
pp. or more distant from the mean 90% effect, which
also shows that the relative scale better captured the ob-
served β2-agonist effect compared with the use of a sin-
gle uniform 28 percentage point improvement, which
had median residual of 10.8 pp.
In our study, the primary comparison of the absolute
and the relative scales was based on IPD, since the wide
distribution of FEV1 declines in the IPD analysis results
in greater statistical power to compare intercepts and
slopes. We also compared the absolute and relative
scales on the basis of study-level data of 44 trials, but no
superiority of the relative scale was seen in that compari-
son, indeed absolute scale seemed to be slightly better
(Table 4). In addition, no superiority of relative scale
over the absolute scale was seen in standard meta-
analyses (Fig. 5a and b). These discrepancies between
the analyses based on IPD (Fig. 2) and on the study-level
data are examples of the “ecological fallacy”. In order to
avoid the potential for the ecological fallacy introduced
by study-level analyses, whenever feasible, examination
of IPD has been recommended [42–44]. Thus, analysis
of the study-level data alone (Table 4) or the comparison
of standard meta-analyses (Fig. 5a and b) would have led
to a false conclusion that the absolute scale is better or
at least not worse than the relative scale.
Nevertheless, even though the analyses of the study-
level data did not yield valid comparison of the absolute
and relative scales, the study-level estimate calculated
from 44 trials for the relative effect was quite similar
with the estimate from the IPD analysis of 14 trials: 77%
vs. 90% improvement in the exercise-induced FEV1 de-
cline, respectively. This divergence in estimates can be
partly explained by the different sets of studies that were
compared. The standard study-level meta-analyses of the
14 studies which had IPD available reached relative
effect estimates of 83% and 90% reduction in FEV1 de-
cline, depending on the calculation of the SE (Fig. 5),
very similar to the overall IPD mixed-effects regression
analysis. This latter comparison was based on the same
set of studies.
Most popular statistical software such as the RevMan
of the Cochrane Collaboration do not have an option to
pool continuous outcomes on the relative scale. How-
ever, it is available in the metacont function of the R
package meta [33, 45, 46]. Nevertheless, a simple ap-
proach to pool results of study-level data on the relative
scale when this option is not available in a statistical
program is to normalize the results of the studies by div-
iding the absolute mean effects and their SD values by
the placebo group mean outcome value (Table S3). Such
a transformation can easily be done with a spreadsheet
program and the transformed data can be entered in a
standard statistical program for meta-analysis. This
approach of calculating the relative effect is illustrated in
Fig. 5b. Alternatively, if IPD is available, one can
Hemilä and Friedrich Systematic Reviews           (2019) 8:282 Page 10 of 13
calculate and pool the slopes of linear regression curves
for each study, which usually leads to more narrow SE
estimates and more accurate pooled estimates as shown
in Fig. 5c. However, IPD is rarely available and therefore
calculation of the slope is not often feasible. Further-
more, for many cross-over trials that reported the study-
level data (Fig. 4), the paired SE was not published and
would need to be imputed, but this problem applies to
both the absolute and the relative scales.
In meta-analysis of binary outcomes, relative scale ana-
lysis using effect measures such as risk ratios or odds ra-
tios leads to asymmetric confidence intervals, because
the studies are pooled on the logarithmic scale with
symmetric confidence intervals and then transformed
back. Similarly, in meta-analysis of continuous out-
comes, the findings can be pooled on the logarithmic
scale using ratio effect measures, leading to asymmetric
CIs [5]. However, relative scale effects for continuous
outcomes can also be derived from slopes (Fig. 2), or by
the normalization of the results of the studies by divid-
ing the absolute mean effects and their SD values by the
placebo group mean outcome value (Table S3) [10], both
of which lead to symmetric CIs on the relative scale.
Therefore, CIs of the continuous outcomes are not ne-
cessarily asymmetric.
The distribution of the relative effects at the individual
level is skewed (Fig. 3). Therefore, the median relative
effect might appear a more useful descriptive estimate
than the mean relative effect. Study-level meta-analyses
cannot find the median effect nor can they describe the
distribution of the individual-level effects such as the
interquartile range. Thus, the IPD analysis can give im-
portant information additional to the study-level ana-
lyses. In our case, the difference between the mean effect
of 90% and the median effect of 88% prevention of EIB
is minor. Nevertheless, the great variation in the
individual-level effects indicates that the efficacy of a
particular β2-agonist in protecting against EIB needs to
be assessed at the individual level (Fig. 3).
This study was motivated by Bonini’s meta-analysis on
β2-agonists for exercise-induced FEV1 declines and their
use of the absolute scale in the analysis of study results
[11]. However, the absolute scale, either as percentage
point differences or as volume differences (measured in
Liters), has been used in the analysis of FEV1 changes in
several other meta-analyses of the Cochrane Library
[47–53]. Thus, the superiority of the relative scale is not
just an issue relevant to Bonini’s meta-analysis. For
example, one of the Cochrane reviews [53] estimated the
effect of vitamin C on EIB on the absolute scale and de-
scribed the effect of vitamin C five minutes after exercise
in the Schachter (1982) trial [54] as follows: “No signifi-
cant difference between vitamin C and placebo: Vitamin
C mean: –0.24 (SE ± 0.06) L/s, Placebo mean: –0.44
(SE ± 0.14) L/s, t = 2.13 (P = 0.057)” [53]: Table 2.
However, the slope of a linear regression analysis of
the Schachter study [54], which had reported the IPD,
indicated that vitamin C’s relative decrease in FEV1
decline was highly significant: 55% (95% CI: 32 to
78%; P = 0.0003) [55]. This difference in P-values also
illustrates that the calculation of the absolute effect,
which is the custom in the Cochrane reviews, can
lead to false negative conclusions.
Our study did not intend to reproduce Bonini’s main
meta-analysis, which was labeled Analysis 1.1 in their
paper [11]. There were several errors and data extraction
inconsistencies, some of which were severe, see Add-
itional file 1: Table S4. We used Bonini’s review as an
example to demonstrate that the calculation of absolute
effects can lead to suboptimal effect estimates. Similar to
Bonini’s analysis, we combined different β2-agonists to
calculate one single estimate of effect. We took this ap-
proach because our primary goal was to compare two
different methods in the analysis of FEV1 changes rather
than estimating the effectiveness of a particular β2-agon-
ist, or a particular experimental protocol for conducting
an exercise test. If one β2-agonist or protocol is less ef-
fective than another, the lower effectiveness would be
analyzed in both ways and, thereby, would contribute
equally to both the relative and absolute scale analysis.
We tried to reduce the heterogeneity of comparisons by
selecting salbutamol (or if not tested, salmeterol) when
several β2-agonists were investigated in the same report,
the shortest delay between β2-agonist administration and
exercise test when exercise tests were repeated several
times after the administration of a β2-agonist, and pre-
drug FEV1 as baseline when possible. Furthermore, we
took into account the variations in β2-agonists and the
conduct of exercise tests used among different trials by
using the β2-agonist and the trial as clustering variables
in the analyses.
Friedrich et al. compared the relative and absolute
scales for diverse continuous outcomes and showed that,
on average, the relative scale led to lower heterogeneity
compared with the absolute scale indicating that the
former is more informative [5–7]. In addition, previous
analyses demonstrated that the analysis of effects on the
duration of diseases and comparable outcomes is more
informative on the relative scale than on the absolute
scale [8–10]. However, there are many different kinds of
contexts where continuous outcomes are generated and,
therefore, the relative scale is not always applicable. Ap-
parently, one requirement for using the relative scale is
that there is a relevant 0% to 100% scale for the meas-
urement. Such requirements are not always satisfied. For
example, there are no reasonable 0% target levels for
body weight, body temperature or blood pressure. In
such cases, the relative scale may not be ideal.
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Since in many contexts the relative scale is more in-
formative in the analysis of continuous outcomes, the
option to use the relative scale should be made widely
available in meta-analysis software so that researchers
can compare and decide themselves which scale is most
suitable for their particular outcome.
Conclusions
Compared with the absolute scale, the relative scale cap-
tures more effectively the variation in the effects of β2-
agonists on exercise-induced FEV1 declines. The abso-
lute scale has been widely used in the analysis of FEV1
changes and it may have led to sub-optimal statistical
analysis in some cases. The choice between the absolute
scale and the relative scale should be determined on the
basis of biological reasoning and empirical testing to
identify the scale that leads to lower heterogeneity. The
relative scale option should be made available for meta-
analysis software. Meanwhile the transformation to the
relative scale can be easily calculated with spreadsheet
programs and the transformed data can be analyzed with
standard meta-analysis software.
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